Habib, F K and Ross, M and Tate, R and Chisholm, G D (1997) Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Clinical Endocrinology, 46 (2). pp. 137-44. ISSN 0300-0664Full text not available in this repository. (Request a copy from the Strathclyde author)
The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.
|Keywords:||5-alpha reductase inhibitors, aged, androgens, androstenedione, dihydrotestosterone, double-blind method, finasteride, humans, prostate, prostate-specific antigen, prostatic hyperplasia, testosterone, Therapeutics. Pharmacology, Endocrinology, Diabetes and Metabolism|
|Subjects:||Medicine > Therapeutics. Pharmacology|
|Department:||Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences|
|Depositing user:||Pure Administrator|
|Date Deposited:||02 Nov 2011 11:02|
|Last modified:||04 May 2016 20:29|